

MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.
You can purchase shares of MapLight Therapeutics (NASDAQ:MPLT) through any online brokerage.
Other companies in MapLight Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
MapLight Therapeutics has a consensus price target of $32.45.
The stock price for MapLight Therapeutics (NASDAQ: MPLT) is $7.37 last updated November 16, 2026 at 7:15 AM EST.
There are no upcoming dividends for MapLight Therapeutics.
MapLight Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for MapLight Therapeutics.
MapLight Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for...